3 Key Questions When Developing The Integrated Summary Of Safety (ISS)
Source: Rho
By Rob Woolson
A New Drug Application (NDA) covers information about a product from inception through clinical trials. The integrated summary of safety (ISS) is a section of the NDA that provides comprehensive safety information collected throughout the development program. The goal of the ISS is to characterize the overall safety profile of the drug and to identify risks that should be included on the product label. This article discusses three key questions to address as a part of your ISS analysis plan.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more